First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study.

PLoS One · 2015 · PMC4366075 · PMID 25789616

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

failed to reach significancep = 0.06so close (0.05 < p ≤ 0.1)

In the two phase III studies of solazenumab this mAb failed to reach the primary endpoints such as improvement of scores on cognitive function and activities of daily living although cognition was positively influenced in one trial but failed to reach significance in the other (p = 0.06) [ 18 ].

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.